Gronchi, AMiah, A BDei Tos, A PAbecassis, NBajpai, JBauer, SBiagini, RBielack, SBlay, J YBolle, SBonvalot, SBoukovinas, IBovee, J V M GBoye, KBrennan, BBrodowicz, TBuonadonna, ADe Álava, EDel Muro, X GDufresne, AEriksson, MFagioli, FFedenko, AFerraresi, VFerrari, AFrezza, A MGasperoni, SGelderblom, HGouin, FGrignani, GHaas, RHassan, A BHecker-Nolting, SHindi, NHohenberger, PJoensuu, HJones, R LJungels, CJutte, PKager, LKasper, BKawai, AKopeckova, KKrákorová, D ALe Cesne, ALe Grange, FLegius, ELeithner, ALopez-Pousa, AMartin-Broto, JMerimsky, OMessiou, CMir, OMontemurro, MMorland, BMorosi, CPalmerini, EPantaleo, M APiana, RPiperno-Neumann, SReichardt, PRutkowski, PSafwat, A ASangalli, CSbaraglia, MScheipl, SSchöffski, PSleijfer, SStrauss, DStrauss, SSundby Hall, KTrama, AUnk, Mvan de Sande, M A Jvan der Graaf, W T Avan Houdt, W JFrebourg, TCasali, P GStacchiotti, SESMO Guidelines Committee, EURACAN and GENTURIS. Electronic address: clinicalguidelines@esmo.org2025-01-072025-01-072021-07-22https://hdl.handle.net/10668/27225enClinical Practice Guidelinedesmoidretroperitoneal sarcomasarcomasoft tissue sarcomasuterine sarcomaFollow-Up StudiesHumansSarcomaSoft Tissue Neoplasmsresearch article34303806open access10.1016/j.annonc.2021.07.0061569-8041http://www.annalsofoncology.org/article/S0923753421021840/pdf